Dose-related effects of growth hormone on IGF-I and IGF-binding protein- 3 levels in non-islet cell tumour hypoglycaemia

European Journal of Endocrinology

Volumn 139, Issue 5, 1998, Pages 532-536

  Drake, W M ^a   Miraki, F ^a   Siddiqi, A ^a   Yateman, M ^a   Barnes, N C ^b   Camacho Hubner C ^a   Monson, J P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; MALE; PANCREAS TUMOR; PRIORITY JOURNAL;

EID: 0031736126     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1390532     Document Type: Article

References (11)

1. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ & Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in non-islet cell tumour hypoglycaemia. Journal of Clinical Endocrinology and Metabolism 1995 80 2700-2708.
2. Khaleeli A, Perumainar M, Spedding AV, Teale JD & Marks V. Treatment of tumour induced hypoglycaemia with human growth hormone. Journal of the Royal Society of Medicine 1992 85 303.
3. Morrell DJ, Dadi H, More J et al. A monoclonal antibody to human insulin-like growth factor-I: characterisation, use in radioimmunoassay and effect on the biological activities of the growth factor. Journal of Molecular Endocrinology 1989 2 201-206.
4. Gowan LK, Hamton B, Hill DJ, Schlueter RJ & Perdue JF. Purification and characterisation of a unique high molecular weight form of insulin-like growth factor-II. Endocrinology 1987 121 449-458.
5. Bowsher RR, Lee W, Apathy JM, O'Brien PJ, Ferguson AL & Henry DP. Measurement of insulin-like growth factor-II in physiological fluids and tissues. An improved extraction procedure and radioimmunoassay for human and rat fluids. Endocrinology 1991 128 805-814.
6. Teale JD, Blum F & Marks V. Alleviation of non-islet cell tumour hypoglycaemia with growth hormone therapy is associated with changes in IGF binding protein-3. Annals of Clinical Biochemistry 1992 29 314-323.
7. Martin JL & Baxter RC. Insulin-like growth factor binding protein-3: biochemistry and physiology. Growth Regulation 1992 2 88-99.
8. Baxter RC & Daughaday WH. Impaired formation of the ternary insulin-like growth factor binding protein complex in patients with hypoglycaemia due to non-islet cell tumours. Journal of Clinical Endocrinology and Metabolism 1991 73 696-702.
9. Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, Lanau F et al. Glucose utilisation in a patient with hepatoma and hypoglycaemia: assessment by a positron emission tomography. Journal of Clinical Investigation 1992 89 1958-1963.
10. 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticoids. Clinical Endocrinology 1996 44 727-731.
11. Jones SE, Baylis PH, Burns C & Ball SG. Non-islet cell tumour-associated hypoglycaemia: the role of somatostatin analogues in treatment. Journal of Endocrinology 1997 (Suppl) 152 94 (Abstract).